Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. We co-hosted this webinar with Impatient to help the audience uncover strategic frameworks, tailored for ATMP access challenges.
Europe is lagging behind in the adoption of ATMPs, as seen in its low profitability and R&D spending compared to other regions. This is largely due to the challenges faced in clinical assessments of ATMPs and the need for innovative pricing and reimbursement pathways to ensure early patient access
Our CEO Herve Lillu recently led a discussion on this topic at the 2020 World Pharma pricing, Evidence, and Market Access Congress. Before we get
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
